A Novel High Dose Chemotherapy Strategy with Bendamustine In Adjunct to Etoposide, Cytarabine and Melphalan (BeEAM) Followed by Autologous Stem Cell Rescue Is Safe and Highly Effective for the Treatment of Resistant/Relapsed Lymphoma Patients: a Phase I-II Study on 44 Patients

MLA

Visani, Giuseppe, et al. “A Novel High Dose Chemotherapy Strategy with Bendamustine In Adjunct to Etoposide, Cytarabine and Melphalan (BeEAM) Followed by Autologous Stem Cell Rescue Is Safe and Highly Effective for the Treatment of Resistant/Relapsed Lymphoma Patients: A Phase I-II Study on 44 Patients.” Blood, vol. 116, no. 21, Nov. 2010, p. 31. EBSCOhost, https://doi.org/10.1182/blood.V116.21.31.31.

APA

Visani, G., Malerba, L., Stefani, P. M., Capria, S., Galieni, P., Gaudio, F., Specchia, G., Meloni, G., Gherlinzoni, F., Giardini, C., Falcioni, S., Loscocco, F., Cuberli, F., Gobbi, M., Santoro, A., Sarina, B., Rocchi, M., & Isidori, A. (2010). A Novel High Dose Chemotherapy Strategy with Bendamustine In Adjunct to Etoposide, Cytarabine and Melphalan (BeEAM) Followed by Autologous Stem Cell Rescue Is Safe and Highly Effective for the Treatment of Resistant/Relapsed Lymphoma Patients: a Phase I-II Study on 44 Patients. Blood, 116(21), 31. https://doi.org/10.1182/blood.V116.21.31.31

Chicago

Visani, Giuseppe, Lara Malerba, Pietro Maria Stefani, Saveria Capria, Piero Galieni, Francesco Gaudio, Giorgina Specchia, et al. 2010. “A Novel High Dose Chemotherapy Strategy with Bendamustine In Adjunct to Etoposide, Cytarabine and Melphalan (BeEAM) Followed by Autologous Stem Cell Rescue Is Safe and Highly Effective for the Treatment of Resistant/Relapsed Lymphoma Patients: A Phase I-II Study on 44 Patients.” Blood 116 (21): 31. doi:10.1182/blood.V116.21.31.31.